Following on the previous comments, the industry has always been supportive of appropriate regulations. We're finding the challenge is the interpretation of the regulations and the implementation of them, and we find that it's biased by the very fact that we are a subset of drugs. We feel that once we're out from that category of drugs, there's a more balanced lens and a more balanced view of how these products are reviewed.
When you're talking about amendments to the regulations, there are some that we would like to see: the opportunity for post-market notification of some of the lower-risk products within that overall low-risk category, so going to market without a review, a post-market notification; removing some of the requirements for specifications right now, because whereas they're in product licensing right now, they belong with good manufacturing practices; and the ability for inspections versus attestations for site licences.
So there are some amendments we'd like to see in the regulations, but in general it's the interpretation and implementation of them.